In the Alzheimer’s brain, microglia diversify into several activation states. What controls this specialization? In a preprint posted to bioRxiv on October 13, scientists led by Martin Kampmann at the ...

Retrotransposons are evolutionarily ancient genes that “jump” around the human genome leaving a slew of repeat nucleotide sequences in their wake. These repeats can disturb normal gene function.

This dataset organizes published data on fluid biomarkers for Alzheimer’s disease and other related conditions. Measurements of biomarker levels from cerebrospinal fluid and blood in non-AD conditions ...

This transgenic model of tauopathy expresses MAPT with the P301S mutation, which is associated with autosomal-dominant disease in humans. The hTau.P301S model recapitulates several molecular, cellular ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Against classical music and visual backdrops evoking Vienna, where the second AAT-AD/PD conference was to be held, the meeting instead unfolded Netflix-style. In this surreal age of COVID-19, the ...

The slight slowing of cognitive decline achieved by Leqembi and perhaps by Aduhelm has revived debate around how much change is needed to be “clinically meaningful.” Two recent papers—one a report ...

With two anti-amyloid antibodies now in clinical use, improving the safety of these treatments is front and center on clinicians’ minds. In the year since lecanemab was approved by the Food and Drug ...

Rare variants in TREM2 and PLCG2 influence a person’s odds of developing Alzheimer’s disease, but that is far from all the two genes have in common. According to a study published June 8 in Nature ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

A routine shunt surgery improves clinical care for people with hydrocephalus. Nearly half have Alzheimer's pathology, offering a natural model of LOAD. Every week, neurosurgeons supply ...